LivaNova PLC Stock: price and insider trades · United States

From a competitive standpoint, LivaNova occupies a niche but strategically attractive position. It does not compete on scale alone; rather, its moat is built on product specialization, regulatory know-how, clinical relationships, hospital integration and a long product cycle. In epilepsy, the company benefits from a differentiated therapy category and increasing evidence generation. In cardiopulmonary, it remains a meaningful supplier of mission-critical systems used in complex surgical environments. This focused structure supports margin potential, but the business remains sensitive to reimbursement decisions, regulatory approvals, product liability risks and clinical uptake.

LivaNova’s key products and services therefore include VNS Therapy, cardiopulmonary and perfusion systems, and emerging digital/remote monitoring capabilities linked to its treatment platforms. Geographically, the company is global, with operations across North America, Europe and Asia, and a workforce of roughly 3,300 employees in 34 countries as of year-end 2025. Recent milestones have included double-digit revenue growth, raised guidance, improved U.S. Medicare reimbursement for VNS Therapy procedures, FDA approval for a cloud-based digital health platform, and U.S. approval for aura6000 in moderate-to-severe obstructive sleep apnea. For international equity investors, LivaNova represents a specialized medtech name combining defensive healthcare characteristics with innovation-driven upside and execution-sensitive growth potential.